Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
11.17
-0.14 (-1.24%)
Sep 10, 2026, 4:00 PM EDT - Market closed
Keros Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 15.01 | 244.06 | 3.55 | 0.15 | - | 20.1 | |
Revenue Growth | -93.55% | 6774.96% | 2250.99% | - | - | - |
Cost of Revenue | 73.36 | 127.14 | 173.63 | 135.26 | 87.27 | 55.14 |
Gross Profit | -58.35 | 116.92 | -170.08 | -135.11 | -87.27 | -35.04 |
Selling, General & Admin | 40.12 | 46.35 | 40.75 | 34.83 | 27.53 | 21.33 |
Operating Expenses | 40.12 | 46.35 | 40.75 | 34.83 | 27.53 | 21.33 |
Operating Income | -98.47 | 70.57 | -210.83 | -169.94 | -114.79 | -56.37 |
Interest Expense | - | - | - | - | -0 | -0 |
Interest & Investment Income | 15.58 | 24.87 | 23.5 | 14.76 | 3.64 | 0.03 |
Currency Exchange Gain (Loss) | - | - | - | -0.21 | -0.61 | - |
Other Non Operating Income (Expenses) | -0.21 | -0.54 | 0.28 | 2.4 | 7.08 | -0.38 |
EBT Excluding Unusual Items | -83.1 | 94.9 | -187.05 | -152.99 | -104.68 | -56.73 |
Merger & Restructuring Charges | -3 | -3 | - | - | - | - |
Pretax Income | -86.1 | 91.9 | -187.05 | -152.99 | -104.68 | -56.73 |
Income Tax Expense | -2.94 | 4.88 | 0.3 | - | - | 2.01 |
Net Income | -83.16 | 87.01 | -187.35 | -152.99 | -104.68 | -58.74 |
Net Income to Common | -83.16 | 87.01 | -187.35 | -152.99 | -104.68 | -58.74 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 27 | 37 | 37 | 29 | 25 | 23 |
Shares Outstanding (Diluted) | 27 | 38 | 37 | 29 | 25 | 23 |
Shares Change | -33.15% | 1.13% | 27.13% | 16.66% | 8.17% | 50.48% |
EPS (Basic) | -3.10 | 2.34 | -5.00 | -5.20 | -4.15 | -2.52 |
EPS (Diluted) | -3.10 | 2.30 | -5.00 | -5.20 | -4.15 | -2.52 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -48.49 | 105.95 | -162.8 | -126.97 | -71.3 | -63.17 |
Free Cash Flow Per Share | -1.81 | 2.80 | -4.35 | -4.31 | -2.83 | -2.71 |
Gross Margin | - | 47.91% | - | - | - | -174.34% |
Operating Margin | -655.84% | 28.91% | -5938.96% | -112543.71% | - | -280.46% |
Profit Margin | -553.88% | 35.65% | -5277.55% | -101319.21% | - | -292.26% |
Free Cash Flow Margin | -322.94% | 43.41% | -4585.91% | -84087.42% | - | -314.29% |
EBITDA | -96.87 | 72.08 | -209.6 | -169.13 | -114.12 | -56 |
EBITDA Margin | - | 29.53% | - | - | - | -278.58% |
D&A For EBITDA | 1.6 | 1.51 | 1.23 | 0.82 | 0.67 | 0.38 |
EBIT | -98.47 | 70.57 | -210.83 | -169.94 | -114.79 | -56.37 |
EBIT Margin | - | 28.91% | - | - | - | -280.46% |
Effective Tax Rate | - | 5.31% | - | - | - | - |
Revenue as Reported | 15.01 | 244.06 | 3.55 | 0.15 | - | 20.1 |